segunda-feira, 5 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 17, 2026

Stock market today: Dow, S&P 500, Nasdaq edge higher in volatile trading as Wall Street assesses AI fears

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq edge higher in volatile trading as Wall Street assesses AI fears US stocks edged higher Tuesday in volatile trading as Wall Street continued assessing the AI jitters that have hammered markets in recent weeks…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If US negotiations aim to eliminate Iran's nuclear energy, there is no room for negotiation; determining the outcome of negotiations in advance is wrong and foolish

    80% confidence
  • AI is fundamentally increasing electricity demand across the technology sector, and geothermal power is uniquely positioned to deliver reliable, carbon-free power to support that growth

    80% confidence
  • The Netflix merger is in the best interests of WBD shareholders due to the tremendous value it provides with a clear path to achieve regulatory approval

    80% confidence
  • Nvidia has key investor topics ahead of earnings: higher component costs impacting expected mid-70s gross margins, updates on Anthropic/OpenAI investments, inference competition, and impact of Groq licensing agreement

    80% confidence
  • Corporate profits are rising while labor income falls, fueling a K-shaped economy; the split is reinforced by rallies in financial and real assets concentrated among higher- and middle-income households

    80% confidence
  • Despite short-term softness, the structural drivers supporting gold remain firmly in place, driven by central bank buying, geopolitical fragmentation, and portfolio diversification

    80% confidence
  • Weak consumer sentiment, heightened uncertainty, and significant volatility weighed on category growth and impacted consumer purchase patterns, contributing to lowered 2026 outlook

    80% confidence
  • Wedbush maintained an Outperform rating and $350 price target on Apple

    80% confidence
  • It remains to be seen whether wages and salaries recoup some of their lost ground relative to corporate profits; higher profits relative to wages are yet another driver of a K-shaped economy

    80% confidence
  • The recent worry and sell-off in Apple's shares is unwarranted; Apple's AI strategy and advanced AI features remain on track for summer release

    80% confidence
  • Iran and the US reached a general agreement on a set of guiding principles for a potential nuclear deal

    80% confidence
  • While the company is making meaningful progress in strengthening its remarkability for long-term sustainable growth, progress has come amid a more challenging backdrop

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,340 documentos-fonte arquivados
Consulte estes dados → isubstrate.com